MAVEN Program for Enhancing Diversity in Scientific Leadership

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Northwell Health

Disqualifiers: Years from degree, Under-represented, Grant funding

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 2

160 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to increase the number of qualified women and minority scientists in senior positions by testing an educational program called MAVEN. The program combines virtual learning and ongoing mentorship to determine its impact on career satisfaction, academic productivity, and leadership roles. Participants will either join the MAVEN program or be in a control group without mentoring. Scientists who have held their terminal degree for 10 to 15 years, identify with under-represented groups, and possess a significant research grant may be well-suited for this trial. As a Phase 2 trial, this research measures the effectiveness of the MAVEN program in an initial, smaller group of participants.

Will I have to stop taking my current medications?

The trial information does not specify whether participants need to stop taking their current medications.

What prior data suggests that the MAVEN program is safe for participants?

Research shows that the MAVEN program emphasizes leadership training, mentorship, and career development, particularly for women and minorities in science. Since MAVEN involves educational sessions and mentoring, it does not have side effects like those associated with drug treatments. Studies have found that similar programs supporting career growth are generally well-received. Participants frequently report positive experiences, such as increased career satisfaction and improved professional connections. Thus, MAVEN is expected to be very safe. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the MAVEN Program for Enhancing Diversity in Scientific Leadership because it aims to address the critical need for diversity in scientific fields by enhancing leadership skills among underrepresented groups. Unlike traditional programs that may not focus specifically on mentorship, MAVEN is designed to provide targeted mentoring and guidance, which could lead to more inclusive and effective scientific leadership. This innovative approach has the potential to create a more diverse and equitable scientific community, which is crucial for generating a wider range of perspectives and ideas in research.

What evidence suggests that the MAVEN program could be effective for enhancing diversity in scientific leadership?

Research has shown that the MAVEN program, which participants in this trial may receive, improves job satisfaction and leadership skills for women and minority scientists. Early results indicated that participants learned important skills to advance their careers. The program aims to increase job satisfaction, boost academic work, and build professional connections. MAVEN offers online educational sessions and ongoing mentorship to help participants reach leadership roles. Overall, the MAVEN initiative is expected to diversify the scientific workforce by preparing underrepresented groups for senior positions. ^{2 3 4 6 7}

Who Is on the Research Team?

Karina Davidson, PhD, MASc

Principal Investigator

Northwell Health

Are You a Good Fit for This Trial?

The MAVEN trial is for scientists who are 10 to 15 years from their terminal degree, have at least one funded R01 level grant, and belong to an ethnicity, race or gender under-represented in senior faculty roles. It's not for those outside the 10-15 year range or who don't meet the diversity criteria.

Inclusion Criteria

I received my highest degree in my field 10-15 years ago.

I belong to an under-represented group in senior faculty levels.

Have one or more funded R01 level grant (or equivalent level grant)

Exclusion Criteria

I do not belong to an under-represented group in senior faculty levels.

Do not have one or more funded R01 level grant (or equivalent level grant)

I received my highest degree in my field either less than 10 years ago or more than 15 years ago.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Virtual Institutes

Participants in the MAVEN group receive two 7-day virtual institutes focused on career planning and leadership

2 weeks

2 virtual sessions

Mentorship and Networking

10 months of mentorship, networking, and conduct of institutional change projects

10 months

Follow-up

Participants are monitored for changes in career satisfaction, academic productivity, network size, and leadership ascension

5 years

What Are the Treatments Tested in This Trial?

Interventions

• MAVEN

Trial Overview MAVEN is testing an educational program with virtual sessions and mentorship aimed at improving career satisfaction, productivity, networking, and leadership positions among minority senior scientists.

How Is the Trial Designed?

Group I: MAVEN Experimental Treatment 1 Intervention

Group II: Control Active Control 1 Intervention

Participants enrolled in the control group will receive no mentoring activities but will complete all study measures and assessments.

Who Is Running the Clinical Trial?

Northwell Health

Lead Sponsor

Trials

481

Recruited

470,000+

National Institutes of Health (NIH)

Collaborator

Trials

2,896

Recruited

8,053,000+

National Institute of General Medical Sciences (NIGMS)

Collaborator

Trials

315

Recruited

251,000+

Published Research Related to This Trial

A review of 99 completed allergic rhinitis trials found that while adverse events (AEs) were fully reported in ClinicalTrials.gov, only 46.7% of corresponding publications provided complete AE reporting, highlighting a significant gap in transparency.

Inconsistencies were prevalent in 95.6% of the publications, with discrepancies in the number and types of AEs reported, indicating a need for improved reporting standards to enhance patient safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Reporting of the safety from allergic rhinitis trials registered on ClinicalTrials.gov and in publications: An observational study. Paladin, I., Pranić, SM.[2022]

The implementation of a computerized data management system for clinical trials significantly reduced transcription errors and overlooked adverse events, with errors dropping from 17% to 0% and overlooked events from 35% to 3%.

Using the computerized system also decreased the time needed to evaluate clinical information and report adverse events by 2-4 months, enhancing compliance with regulations and allowing for quicker identification of potential risks to patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of benefits derived from a computerized data management system for clinical trials data. Elting, LS., Bodey, GP.[2018]

Citations

1. reporter.nih.gov reporter.nih.gov/project-details/10685470

MAVEN: Developing Diverse Senior Scientists Leaders To achieve the MAVEN long-term objective, MAVEN scientists will be provided the skills to attain: 1) increased career satisfaction (primary outcome); 2) peak ...

2. elifesciences.org elifesciences.org/articles/69063

Equity, Diversity and Inclusion: Introducing the MAVEN ... A program called MAVEN that has been designed to teach leadership skills to mid-career women scientists, particularly those from underrepresented groups.

3. clinicaltrials.gov clinicaltrials.gov/study/NCT05171101

The MAVEN Senior Scientist Initiative MAVEN is an education training program designed to expand the national pool of qualified women and minority candidates for senior scientist positions across ...

4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC8149121/

Introducing the MAVEN Leadership Training Initiative to ... A program called MAVEN that has been designed to teach leadership skills to mid-career women scientists, particularly those from underrepresented groups.

5. researchgate.net researchgate.net/publication/351858138_Introducing_the_MAVEN_Leadership_Training_Initiative_to_diversify_the_scientific_workforce

Introducing the MAVEN Leadership Training Initiative to ... In this article, we focus on efforts to encourage mid-career women, particularly women of color, to move into leadership positions in science ...

6. withpower.com withpower.com/trial/phase-2-4-2021-bdd3a

MAVEN Program for Enhancing Diversity in Scientific ... This Phase 2 medical study run by Northwell Health needs participants to evaluate whether MAVEN will have tolerable side effects & efficacy for patients ...

7. elifesciences.org elifesciences.org/articles/69063/figures

Equity, Diversity and Inclusion: Introducing the MAVEN ... The MAVEN Initiative has been designed to encourage mid-career women scientists, particularly women of color, to move into leadership ...